MONTREAL, QUEBEC--(CCNMatthews - Nov. 15, 2005) - MethylGene Inc. (TSX:MYG) a biopharmaceutical company, today announced interim results regarding MGCD0103, its isotype-selective HDAC inhibitor for cancer, in four posters presented during the 18th EORTC-NCI-AACR (European Organisation for Research and Treatment of Cancer, National Cancer Institute, American Association for Cancer Research) International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia on November 14, 2005. Ongoing clinical data for MGCD0103 in solid tumours demonstrated prolonged disease stabilization in three patients with the most significant side-effect being reversible fatigue. Of particular note, is the apparent lack of significant hematological and cardiac side effects with MGCD0103. Data disclosed at the conference included the chemical structure of MGCD0103, the specific HDAC isoforms targeted by MGCD0103, the synergistic antitumour activity of MGCD0103 combined with gemcitabine in pancreatic and lung cancer models in vivo, and the synergistic anticancer activity of MGCD0103 with interferon alpha in multiple myeloma cell lines.
